Life-saving gene therapies are blocked by the body’s own defenses, leaving countless patients unable to access revolutionary treatments. As of 2024, the FDA has approved 36 gene therapies reflecting the rapid advancements in this field. In 2023 alone, seven gene therapies received approval. The pipeline is robust, with over 500 gene therapies in various stages of development, and senior FDA leadership anticipates that 10 or more new gene therapies will be approved annually by 2025. Effective immune suppression is now critical to successful gene delivery and maintaining long-term results.
Company
Our mission is to develop clinically meaningful antibody suppression and enable effective therapies
“Too many people cannot receive a life changing gene therapy due to their own antibodies. We aim to bring the promise of gene therapy to every patient and make it last.”
Charles AskewCo-founder & President
Why it matters
Gene therapy is growing rapidly – suppression of neutralizing antibodies (Nabs) is critical to successful treatment.
1 in 10
people suffer from a rare genetic disease
30-60%
of patients are ineligible due to NAbs
Once
is the only shot patients have now at a cure